CN103720791B - A kind of strong medicine preventing and treating post-stroke depression and preparation method thereof - Google Patents
A kind of strong medicine preventing and treating post-stroke depression and preparation method thereof Download PDFInfo
- Publication number
- CN103720791B CN103720791B CN201310705502.XA CN201310705502A CN103720791B CN 103720791 B CN103720791 B CN 103720791B CN 201310705502 A CN201310705502 A CN 201310705502A CN 103720791 B CN103720791 B CN 103720791B
- Authority
- CN
- China
- Prior art keywords
- dunn
- stroke depression
- strong medicine
- post
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 45
- 206010070606 Post stroke depression Diseases 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 239000012567 medical material Substances 0.000 claims abstract description 30
- 241001074085 Scophthalmus aquosus Species 0.000 claims abstract description 18
- 241000913770 Millettia pulchra Species 0.000 claims abstract description 17
- 241000505911 Tadehagi Species 0.000 claims abstract description 17
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 20
- 239000000706 filtrate Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 13
- 235000019640 taste Nutrition 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 12
- 238000010992 reflux Methods 0.000 claims description 4
- 238000002481 ethanol extraction Methods 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 22
- 210000004369 blood Anatomy 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 16
- 239000000203 mixture Substances 0.000 abstract description 12
- 231100000614 poison Toxicity 0.000 abstract description 5
- 239000003440 toxic substance Substances 0.000 abstract description 5
- 230000001360 synchronised effect Effects 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 description 35
- 208000006011 Stroke Diseases 0.000 description 16
- 239000002671 adjuvant Substances 0.000 description 15
- 208000002193 Pain Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 206010008190 Cerebrovascular accident Diseases 0.000 description 9
- 235000020357 syrup Nutrition 0.000 description 9
- 239000006188 syrup Substances 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 230000010354 integration Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 6
- 241000345998 Calamus manan Species 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 235000012950 rattan cane Nutrition 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 208000014644 Brain disease Diseases 0.000 description 3
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 3
- 208000020401 Depressive disease Diseases 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 208000032274 Encephalopathy Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 210000001259 mesencephalon Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 235000010199 sorbic acid Nutrition 0.000 description 3
- 239000004334 sorbic acid Substances 0.000 description 3
- 229940075582 sorbic acid Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 241000143476 Bidens Species 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241001289529 Fallopia multiflora Species 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Chemical class 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 239000001913 cellulose Chemical class 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Chemical class 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 201000003995 melancholia Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920001223 polyethylene glycol Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000021251 pulses Nutrition 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 235000020374 simple syrup Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 240000000782 Anisomeles indica Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017886 Gastroduodenal ulcer Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 108010010803 Gelatin Chemical class 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 241001640034 Heteropterys Species 0.000 description 1
- 244000025221 Humulus lupulus Species 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 241000561703 Kadsura heteroclita Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- SNIXRMIHFOIVBB-UHFFFAOYSA-N N-Hydroxyl-tryptamine Chemical class C1=CC=C2C(CCNO)=CNC2=C1 SNIXRMIHFOIVBB-UHFFFAOYSA-N 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 244000174716 Phaseolus caracalla Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241000758724 Schisandraceae Species 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 240000001547 Tadehagi triquetrum Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000880 dysequilibrium Toxicity 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000008519 endogenous mechanism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Chemical class 0.000 description 1
- 229920000159 gelatin Chemical class 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of strong medicine preventing and treating post-stroke depression and preparation method thereof.Said composition is that raw material is prepared from by Herba Desmodii Triquetri (Herba Tadehagi Triquetri), Caulis Polygoni Multiflori, dry root of Millettia pulchra(Dunn)Kurz var.laxior(Dunn)Z.Wei, bright red brill, the Radix Paeoniae Alba five kinds of medical materials.Present invention also offers the preparation method of the strong medicine of this control post-stroke depression.Strong medical instrument provided by the invention has the smooth QI and blood effect of heat-clearing and toxic substances removing, expelling wind and removing dampness, tune, and Shi Long road is unobstructed, and conduction is normal, thus reaches the physiological status that QI and blood is in harmonious proportion, three gas are synchronous.Evident in efficacy to control post-stroke depression.
Description
Technical field
The present invention relates to pharmaceutical sanitary field, be specifically related to a kind of strong medicine preventing and treating post-stroke depression and preparation method thereof.
Background technology
Post-stroke depression (Post-strokedepression, PSD) is a kind of affective disorder disease comprising the complexity of multiple mental symptom and somatization occurred after a stroke.Main manifestations is that lasting depressed, retardation of thinking and content of thought obstacle and bulesis reduce, thus causes the clinical malaise symptoms of the multisystem such as a series of gastrointestinal tract, cardiovascular, breathing, and even world-weary and behavior such as suicides grade appears in some patients.
The sickness rate of a large amount of clinical report prompting post-stroke depressions is higher, and foreign literature reports that its sickness rate is 25%-79%, and great majority are at 40%-50%.And there is research display, the comprehensive rehabilitation of post-stroke depression to patients with cerebral apoplexy has obvious negative effect, being mainly manifested in extended hospital stay, mortality rate raises, make physical disease treat complicated, to affect limbs and language rehabilitation etc., is the independent hazard factor affecting patient's functional rehabilitation and Stroke Recurrence.So carry out early diagnosis to post-stroke depression and active treatment is very important, prevent targetedly to seem even more important to depression at post-stroke.
The pathogenesis of PSD it be not immediately clear, doctor trained in Western medicine mainly contains two kinds of theories: one is constitutional endogenous mechanism theory, and namely the generation of PSD is relevant with the dysequilibrium caused after brain damage between norepinephrine (NE) and 5 one hydroxytryptamines (5-HT).Two is reactive machine-processed theories, and namely the various factors such as family, society, physiology causes the physiology of post-stroke and psychological balance imbalance and causes reactive depressive state.What current western medical treatment PSD application was more is that moclobemide, serotonin reuptake inhibitors (SSRI) are as fluorine west, spit of fland paroxetine etc., it is rapid-action, depression and anxiety can be treated simultaneously, but but have and bring out hypertensive danger and further apoplexy.
Post-stroke depression belongs to the traditional Chinese medical science " apoplexy " " melancholia ".Namely have in "Nei Jing" " worried person, gas-tight plug and obstructed ".Jing-Yue Complete Works is thought: " if melancholy patient, belonging to extreme deficiency syndrome, this nothing domination of pathogen ".Melancholy sick (i.e. depression) this name of disease is clearly proposed." danxi's experiential therapy " founds " six kinds of stagnation-syndromes " opinion, thinks with the stagnation of QI to be elder generation, and then blood, expectorant, heat, wet, food etc. are all strongly fragrantly could be formed." Treatise on the spleen and stomach " day: " all anger sad thoughts is frightened, all damages vigour, husband's YIN-fire flourishing, stagnates by the heart is raw, seven emotions uneasy thus also "." Jing Yue's complete work melancholia " proposes the theory of " stagnation of QI-blood due to disease " and " disease due to stagnation of QI-blood ", " strongly fragrant by the heart ", thinks functional activity of QI being not smooth, and it is pathogenesis core that blood stasis hinders network.Theoretical according to Chinese medical discrimination, the clinical common pattern of syndrome of PSD can be divided into 4 types: obstruction of collateral caused by windphlegm, stagnation of QI due to depression of the liver; Liver-yang is held concurrently high, accumulates in stagnated fire; Blood stasis due to qi deficiency, heart spleen is two to be damaged; Deficiency of the liver and kindey, melancholy is overtaxed one's nerves.Therapeutic Principle is under the major premise of determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, should pay attention to coordinating dispersing liver and promoting blood circulation resolving depression, the method for purging liver-heat resolving depression and mind tranquilizing and the heart calming.
Summary of the invention
The object of this invention is to provide a kind of strong medicine preventing and treating post-stroke depression;
Another object of the present invention is to provide a kind of strong medicament preparation preventing and treating post-stroke depression.
The object of the invention is by following technical scheme realize:
The strong medicine of control post-stroke depression of the present invention is prepared from by the raw material containing following weight portion:
Herba Desmodii Triquetri (Herba Tadehagi Triquetri) 30-70 part, Caulis Polygoni Multiflori 20-50 part, dry root of Millettia pulchra(Dunn)Kurz var.laxior(Dunn)Z.Wei 20-50 part, bright red brill 30-80 part, Radix Paeoniae Alba 5-20 part.
Preferably, be prepared from by the raw material containing following weight portion:
Herba Desmodii Triquetri (Herba Tadehagi Triquetri) 40-60 part, Caulis Polygoni Multiflori 35-45 part, dry root of Millettia pulchra(Dunn)Kurz var.laxior(Dunn)Z.Wei 30-40 part, bright red brill 35-45 part, Radix Paeoniae Alba 10-15 part.
More preferably, be prepared from by the raw material containing following weight portion:
Herba Desmodii Triquetri (Herba Tadehagi Triquetri) 50 parts, Caulis Polygoni Multiflori 40 parts, dry root of Millettia pulchra(Dunn)Kurz var.laxior(Dunn)Z.Wei 35 parts, 40 parts, bright red brill, the Radix Paeoniae Alba 12 parts.
Below crude drug source of the present invention:
Herba Desmodii Triquetri (Herba Tadehagi Triquetri), pulse family beggar-ticks plant gourd tea Desmodiumtriquetrum(L.) DC., is used as medicine with Herb.Xia Qiu gathers, and cleans and chops up, dry.Using fresh herb can be adopted at any time.Micro-hardship, puckery, cool.Heat-clearing and toxic substances removing, removing food stagnancy dampness removing, parasite killing is anticorrosion.For preventing heatstroke, cold, fever, laryngopharynx swelling and pain, nephritis, icterohepatitis, enteritis, bacillary dysentery, infantile malnutrition, vomiting during pregnancy, Fructus Ananadis comosi is poisoning, children's's scleroderma.
Caulis Polygoni Multiflori is rattan or the leaf bine stem of polygonum multiflorum thunb PolygonummultiflorumThunb.With the rattan of leaf, Yu Xia, autumn take.But commodity mostly use rattan, in autumn leaf fall behind extract, removing withe, residual leaf, be cut into the paragraph being about 70 centimetres, be bundled into handle, dry.Sweet micro-hardship, flat.Enter the heart, Liver Channel.Nourish heart, calm the nerves, dredging collateral, dispel the wind.Control insomnia, impairment caused by overstrain, hyperhidrosis, blood deficiency general pain, carbuncle, scrofula, wind skin ulcer scabies.
Dry root of Millettia pulchra(Dunn)Kurz var.laxior(Dunn)Z.Wei, for leguminous plant dredges the root of leaf U.S. flower precipice bean rattan.Autumn, winter excavate, and clean, dry.Sweet in the mouth is micro-pungent, and property is put down, nontoxic.Enter Liver Channel.Dissipating blood stasis, detumescence, pain relieving, allays excitement.Control treating swelling and pain by traumatic injury.
Bright red brill, the root of Schisandraceae Plant abnormity Fructus Schisandrae Sphenantherae Kadsuraheteroclita (Roxb.) Craib., old rattan.Acrid in the mouth, slightly warm in nature.Expelling wind and removing dampness, regulating QI to relieve pain, promoting blood circulation to remove blood stasis, detumescence, relaxing muscles and tendons and activating QI and blood in the collateral.Dispelling the wind and dampness pathogens stomachache, lumbago and skelalgia, sciatica, acute gastroenteritis, chronic gastritis, gastroduodenal ulcer, menstrual pain, puerperal abdonimal pain, puerperal paralysis, traumatic injury.For the brave nine N of 18 brill class medicine bored in the old speckle medicine of 72 wind 104 kinds of classical precious jade medicine five, belong to wind and spray medicine of holding concurrently mutually.
The Radix Paeoniae Alba, this product is the dry root of ranunculaceae plant Radix Paeoniae PaeonialactifloraPall..Summer, Qiu Erji excavate, and clean, and remove end to end and radicula, put in boiling water after boiling rear removing crust or peeling and boil, dry.Bitter, sour, be slightly cold.Return liver, spleen channel.Suppressing the hyperactive liver pain relieving, nourishing blood for regulating menstruation, astringing YIN to stop sweating.Dizzy for having a headache, hypochondriac pain, stomachache, limb pain twin, blood deficiency and yellow complexion, menoxenia, spontaneous perspiration, night sweat.
Another aspect of the present invention there is provided the preparation method that the present invention strengthens the active component of medicine, and the method is the ethanol extraction adopting water extraction or 40-80% concentration expressed in percentage by volume.Concrete preparation method is as follows:
Scheme one: get whole 5 taste medical materials, extracting in water 2-3 time, each amount of water is equivalent to the 6-12 of medical material gross weight doubly, each extraction time is 1-3 hour, merge extractive liquid, filters, when filtrate is concentrated into 70-80 DEG C, relative density is the clear paste of 1.10-1.25, obtains described active component.
Scheme two: get whole 5 taste medical materials, extracting in water 2-3 time, each amount of water is equivalent to the 6-12 of medical material gross weight doubly, each extraction time is 1-3 hour, merge extractive liquid, filters, and when filtrate is concentrated into 70-80 DEG C, relative density is the clear paste of 1.05-1.20, add ethanol, make alcohol content be 40-70%, leave standstill 12-24 hour, filter, when filtrate is concentrated into 70-80 DEG C, relative density is the extractum of 1.10-1.25, obtains described active component.
Scheme three: get whole 5 taste medical materials, with 40-80% alcohol reflux 2-3 time, each ethanol consumption be the 4-10 of medical material total amount doubly, extraction time is 1-3 hour, merge extractive liquid, filters, when filtrate is concentrated into 60-80 DEG C, relative density is the extractum of 1.10-1.25, obtains described active component.
The strong drug composition of control post-stroke depression of the present invention, with pharmaceutically acceptable carrier combination, can make various common dosage forms, as tablet, granule, capsule, oral liquid, syrup etc.
Pharmaceutically acceptable carrier of the present invention includes but not limited to following:
Diluent: starch, Icing Sugar, lactose, dextrin, microcrystalline Cellulose, inorganic salt, sugar alcohols etc.
Wetting agent and binding agent: purified water, ethanol, gelatin, Polyethylene Glycol, cellulose derivative etc.
Disintegrating agent: starch, carboxymethyl starch sodium, cellulose derivative, polyvinylpolypyrrolidone etc.
Lubricant: magnesium stearate, micropowder silica gel, Pulvis Talci, Polyethylene Glycol etc.
Cosolvent: water, ethanol, glycerol, propylene glycol, liquid Paraffin, plant wet goods.
Correctives: sucrose, simple syrup, aromatic, Mel, simple syrup, glycyrrhizic acid and stevioside etc.
Antiseptic: benzoic acid, sorbic acid, propanoic acid, methyl ester, ethyl ester, propyl ester etc.
Method 1: tablet
Get one of scheme one to scheme three gained active component, add tablet and commonly use adjuvant, production method is prepared into Tablets routinely.
Above-mentioned tablet is commonly used adjuvant and is comprised one of diluent, wetting agent, binding agent, disintegrating agent, lubricant or whole.
Method 2: granule
Get one of scheme one to scheme three gained active component, add granule and commonly use adjuvant, production method is prepared into granule of the present invention routinely.
Above-mentioned granule is commonly used adjuvant and is comprised one of diluent, wetting agent, binding agent, disintegrating agent or whole.
Method 3: capsule
Get one of scheme one to scheme three gained active component, add capsule and commonly use adjuvant, production method is prepared into capsule of the present invention routinely.
Above-mentioned capsule is commonly used adjuvant and is comprised one of diluent, wetting agent, binding agent, disintegrating agent, lubricant or whole.
Method 4: syrup
Get one of scheme one to scheme three gained active component, add syrup and commonly use adjuvant, production method is prepared into syrup of the present invention routinely.
Above-mentioned syrup is commonly used adjuvant and is comprised one of correctives, antiseptic, cosolvent or whole.
Method 5: mixture
Get one of scheme one to scheme three gained active component, add mixture and commonly use adjuvant, production method is prepared into mixture of the present invention routinely.
Above-mentioned mixture is commonly used adjuvant and is comprised one of correctives, antiseptic or whole.
Method 6: oral liquid
Get one of scheme one to scheme three gained active component, dissolve after-purification, concentrate, add oral liquid and commonly use adjuvant, production method is prepared into oral liquid of the present invention routinely.
The applicant strengthens with reference to modern pharmacological research achievement on the basis of the strong medicine Coryza Treated by Syndrome Differentiation of doctor at research tradition, and combines through clinical experience for many years, is screened by multiple formulations dosage, thinks that this strong prescription control post-stroke depression is evident in efficacy, is worthy to be popularized.Control post-stroke depression should be paid attention to coordinating dispersing liver and promoting blood circulation resolving depression, purging liver-heat, resolving depression and mind tranquilizing and the heart calming, and in we, Caulis Polygoni Multiflori is put down nontoxic, sweet and slightly bitter taste, enters the heart, Liver Channel, has effect of tranquilizing and blood nourishing, dispelling wind and removing obstruction in the collateral, is principal agent.Herba Desmodii Triquetri (Herba Tadehagi Triquetri), have another name called razor handle, Cordyceps, Anisomeles indica (L.) Kuntze etc., overseas Chinese claims " celestial tea ", is pulse family beggar-ticks plant, and possessing the effect such as heat-clearing and toxic substances removing, removing food stagnancy dampness removing, is female medicine.Dry root of Millettia pulchra(Dunn)Kurz var.laxior(Dunn)Z.Wei is Guangxi Zhuang, Yao nationality's tradition commonly uses ethnic drug, is used for the treatment of blood deficiency dizziness, insomnia, treating swelling and pain by traumatic injury, the diseases such as apoplexy hemiplegia, in recent years, research shows the effects such as beautiful youth loose also has QI invigorating, enriches blood, anti-stress, anti-hypoxia, raising immunity of organisms, is side medicine.Bright red brill is Guangxi Zhuang, Yao nationality's common drug among the people, and belong to Zhuang fire road common medicine, belong to the Yao nationality and bore class medicine, its gas delicate fragrance, puckery, hardship, property is put down, and has expelling wind and removing dampness, regulating QI to relieve pain, the effect of promoting blood circulation and detumescence, can be used for the disease of all asthenia of qi and blood stasis of bloods, is side medicine.Be usually used in rheumatism, lumbar muscle strain, hemiplegia, puerperal paralysis, the disease such as dysmenorrhea treatment.The Radix Paeoniae Alba enters liver, spleen channel, has nourishing blood to suppress the hyperactive liver, pain relieving in slow, and yin fluid astringing receives the merit of antiperspirant, is band medicine.This side has reacted the typical principles of formulating prescriptions of strong doctor, and five medicines share, can heat-clearing and toxic substances removing, dispersing liver and promoting blood circulation, expelling wind and removing dampness, the smooth QI and blood of tune, Shi Long road is unobstructed, and conduction is normal, thus reaches the physiological status that QI and blood is in harmonious proportion, three gas are synchronous, after making patients with cerebral apoplexy, the peaceful gas of the heart is suitable, the generation of the depressed card of prevention.
A kind of strong drug composition preventing and treating post-stroke depression provided by the invention has the following advantages:
1, the strong medicine of control post-stroke depression provided by the invention is safe and effective, have heat-clearing and toxic substances removing, expelling wind and removing dampness, the smooth QI and blood effect of tune, Shi Long road is unobstructed, and conduction is normal, thus reach the physiological status that QI and blood is in harmonious proportion, three gas are synchronous, evident in efficacy to control post-stroke depression.
2, clinical test results display, after treating 4 weeks, the present invention and matched group HAMD mark, and all comparatively treatment is front significantly declines (P<0.05), sleep integration scale score significantly declines (P<0.05) before all comparatively treating, and on Western medicine basis, add therapeutic effect of the present invention be significantly better than matched group, particularly in the time that post-stroke is longer, prevention effect of the present invention is more obvious, not easily produce drug resistance, safe without toxic side effect.The depression using the present invention to prevent and treat post-stroke to produce, can treating both the principal and secondary aspects of a disease, safety high, clinical trial effective percentage can reach 90.0%; Western medicine usually can only temporarily onset, easily repeatedly, and has the danger bringing out hypertension and further apoplexy.
3, the present invention strengthens drug composition formula and rationally innovates, and production cost is low, technique is simple.
Detailed description of the invention
The present invention is further illustrated below by embodiment.It should be understood that embodiments of the invention are for illustration of the present invention instead of limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.
Embodiment 1 syrup
Get Herba Desmodii Triquetri (Herba Tadehagi Triquetri) 3kg, Caulis Polygoni Multiflori 2kg, dry root of Millettia pulchra(Dunn)Kurz var.laxior(Dunn)Z.Wei 2kg, bright red brill 3kg, Radix Paeoniae Alba 0.5kg.By above-mentioned 5 taste medical materials, extracting in water 2 times, twice amount of water is respectively 10 times, 8 times of medical material gross weight, and the extracted twice time is respectively 2 hours, 1 hour, merge extractive liquid, filters, and when filtrate is concentrated into 80 DEG C, relative density is the extractum of 1.10.In extractum, add syrup adjuvant sucrose, sorbic acid, water stirs, obtained syrup.
Embodiment 2 tablet
Get Herba Desmodii Triquetri (Herba Tadehagi Triquetri) 7kg, Caulis Polygoni Multiflori 5kg, dry root of Millettia pulchra(Dunn)Kurz var.laxior(Dunn)Z.Wei 5kg, bright red brill 8kg, Radix Paeoniae Alba 2kg.By above-mentioned 5 taste medical materials, with 40% alcohol reflux 3 times, each ethanol consumption is respectively 10 times, 8 times, 4 times of medical material total amount, 3 hours, 2 hours, 1 hour respectively extraction time, merge extractive liquid, filters, and when filtrate concentrates 60 DEG C, relative density is the extractum of 1.25, add supplementary product starch, ethanol, Pulvis Talci, obtained tablet.
Embodiment 3 mixture
Get Herba Desmodii Triquetri (Herba Tadehagi Triquetri) 4kg, Caulis Polygoni Multiflori 3.5kg, dry root of Millettia pulchra(Dunn)Kurz var.laxior(Dunn)Z.Wei 3kg, bright red brill 3.5kg, Radix Paeoniae Alba 1kg.By above-mentioned 5 taste medical materials, extracting in water 3 times, three amount of water are equivalent to 12 times of medical material gross weight respectively, 8 times, 6 times, 3 hours respectively each extraction time, 2 hours, 1 hour, merge extractive liquid, filter, when filtrate is concentrated into 70 DEG C, relative density is the clear paste of 1.20, add ethanol, alcohol content is made to be 40%, leave standstill 24 hours, filter, it is the extractum of 1.10 that filtrate is concentrated into relative density when filtrate is concentrated into 70 DEG C, add 3 times that purified water ad pond om is medical material gross weight, fill, add mixture adjuvant sucrose, ethyl ester, water, sorbic acid stirs, obtained mixture.
Embodiment 4 oral liquid
Get Herba Desmodii Triquetri (Herba Tadehagi Triquetri) 5kg, Caulis Polygoni Multiflori 4kg, dry root of Millettia pulchra(Dunn)Kurz var.laxior(Dunn)Z.Wei 3.5kg, bright red brill 4kg, Radix Paeoniae Alba 1.2kg.By above-mentioned 5 taste medical materials, extracting in water 2 times, 2 amount of water are equivalent to 10 times, 8 times of medical material gross weight respectively, 2 hours respectively each extraction time, merge extractive liquid, filters, when filtrate is concentrated into 80 DEG C, relative density is the clear paste of 1.15, adds ethanol, makes alcohol content be 50%, leave standstill 24 hours, filter, filtrate is concentrated into 2 times of medical material gross weight, add adjuvant Mel, monoglycosides, benzoic acid, after stirring evenly fine straining, subpackage, sterilizing, obtained oral liquid.
Embodiment 5 tablet
Get Herba Desmodii Triquetri (Herba Tadehagi Triquetri) 6kg, Caulis Polygoni Multiflori 4.5kg, dry root of Millettia pulchra(Dunn)Kurz var.laxior(Dunn)Z.Wei 4kg, bright red brill 4.5kg, Radix Paeoniae Alba 1.5kg.By above-mentioned 5 taste medical material alcohol reflux 2 times, each concentration of alcohol is respectively 80%, 60%, each ethanol consumption is respectively 10 times, 8 times of medical material total amount, extraction time is respectively 4 hours, 3 hours, merge extractive liquid, filters, and when filtrate is concentrated into 80 DEG C, relative density is the extractum of 1.10, add supplementary product starch, ethanol, Pulvis Talci, obtained tablet.
Embodiment 6 capsule
Get Herba Desmodii Triquetri (Herba Tadehagi Triquetri) 5kg, Caulis Polygoni Multiflori 5kg, dry root of Millettia pulchra(Dunn)Kurz var.laxior(Dunn)Z.Wei 3kg, bright red brill 3kg, Radix Paeoniae Alba 1kg.By above-mentioned 5 taste medical materials, extracting in water 3 times, three amount of water are respectively 12 times, 8 times, 6 times of medical material gross weight, three extraction times are respectively 3 hours, 2 hours, 1 hour, merge extractive liquid, filters, and when filtrate is concentrated into 70 DEG C, relative density is the clear paste of 1.25, add supplementary product starch, ethanol, dextrin, magnesium stearate, incapsulate shell, obtained capsule.
Embodiment 7 granule
Get Herba Desmodii Triquetri (Herba Tadehagi Triquetri) 3kg, Caulis Polygoni Multiflori 3.5kg, dry root of Millettia pulchra(Dunn)Kurz var.laxior(Dunn)Z.Wei 4kg, bright red brill 3.5kg, Radix Paeoniae Alba 1.5kg.By above-mentioned 5 taste medical materials, extracting in water 2 times, each amount of water is equivalent to 12 times, 10 times of medical material gross weight respectively, each extraction time is respectively 3 hours, 2 hours, merge extractive liquid, filters, it is the clear paste of 1.05 that filtrate is concentrated into relative density at 80 DEG C, add ethanol, make alcohol content be 70%, leave standstill 12 hours, filter, when filtrate is concentrated into 70 DEG C, relative density is the extractum of 1.25, adds adjuvant Icing Sugar, starch, dextrin, ethanol, obtained granule.
Embodiment 8 powder
Get Herba Desmodii Triquetri (Herba Tadehagi Triquetri) 4.5kg, Caulis Polygoni Multiflori 4.5kg, dry root of Millettia pulchra(Dunn)Kurz var.laxior(Dunn)Z.Wei 2kg, bright red brill 4.5kg, Radix Paeoniae Alba 2kg.Medical material cleans, pulverize, and crosses 80-100 mesh sieve, obtains powder of the present invention.
Clinical efficacy
1, case selection: collect the court and make a definite diagnosis Post-stroke Depression 60 example year March in March, 2011 to 2013 in hospital, be divided into observation group 30 example at random, male 16 example, women 14 example, 45 ~ 76 years old age, mean age (63 ± 9) year, the course of disease 4 ~ 22 weeks, average (13.7 ± 5.1) week; Its midbrain infarction 26 example, cerebral hemorrhage 4 example.Matched group 30 example, male 17 example, women 13 example, 42 ~ 81 years old age, the mean age (62 ± 10) year, the course of disease 3 ~ 23 weeks, average (14.1 ± 5.4) are all; Its midbrain infarction 27 example, cerebral hemorrhage 3 example.The aspect such as type, the course of disease, depression scale scoring, the scoring of sleep integration of two groups of patients sex before the treatment, age, apoplexy, through the equal not statistically significant of statistics comparing difference (P>0.05), has comparability.
2, diagnostic criteria:
Apoplexy according to the diagnostic criteria of the 6th edition national institution of higher learning teaching material " neurological " midbrain infarction in 2008, cerebral hemorrhage, and confirms through head CT or head magnetic resonance examination.Depressed diagnosis is with reference to the diagnostic criteria about caused by cerebrovascular disease mental disorder-post-stroke depression in CCMD-3 (Chinese Spirit Obstacles classification and diagnostic criteria).
3, curative effect determinate standard:
Two groups of patients all carry out Measuring scale assessing in 2 weeks, 4 weeks before treatment and after treatment: with HAMD (24), depression scale is for the standard of curative effect evaluation, specific as follows:
1. cure: HAMD (24) total score <8 divides or deduction rate >75%;
2. effective: before and after HAMD (24) total score, to reduce >50%;
3. take a turn for the better: before and after HAMD (24) total score, reduce >25% and <50%;
4. invalid: to reduce <25% before and after HAMD (24) total score or sb.'s illness took a turn for the worse.
Deduction rate=(before treatment the rear integration of integration-treatment)/treatment front point × 100%.
4, drug use method
Treatment group and matched group all adopt apoplexy conventional therapy and the base therapy such as psychological intervention, Rehabilitation Training in Treating.
Matched group gives Paroxetine Tablets 20mg/ time, 1 times/day;
Treatment group adds with the embodiment of the present invention 4 oral liquid on the basis of matched group, each 70ml, every day 2 times.
5, clinical treatment outcome:
5.1 treatments are after 4 weeks, and treatment group and matched group total effective rate are respectively 90.0% and 76.7%, through x
2after inspection, P=0.166>0.05; Two groups of total effects differences, after rank test, P=0.198>0.05, points out two groups of total effective rates and the equal not statistically significant of total effects difference.In table 1
Comparitive study after 4 weeks treated by table 1
Note: two groups of total effectses and total effective rate contrast P>0.05
5.2 treatments are after 4 weeks, and before and after two groups of case treatments, HAMD scale score compares.After 2 groups of treatments, HAMD scoring is lowered all gradually, all comparatively significantly declines (P<0.05) before treatment after 4 weeks, and between group, comparing difference has statistical significance (P<0.05) in table 2 same period.
Before and after table 2 liang group treatment, HAMD scale score compares
Note: matched group and treatment group treatment front and back paired t-test, * P<0.05; The same period is checked than with t between group, #P<0.05.
5.3 treatments are after 4 weeks, and two groups of sleep integration scale score compare, and all comparatively significantly decline (P<0.05) before treatment after 4 weeks, and between group, comparing difference has statistical significance (P<0.05) in table 3 same period
Before and after table 3 liang group treatment, sleep integration scale score compares
Note: matched group and treatment group treatment front and back paired t-test, * P<0.05; The same period is checked than with t between group, #P<0.05.
Conclusion: after treating 4 weeks, treatment group and the equal not statistically significant of matched group total effective rate; Treatment group and matched group HAMD mark, and all comparatively treatment is front significantly to decline (P<0.05), and treatment group therapeutic effect is significantly better than matched group; Treatment group and matched group sleep integration scale score significantly decline (P<0.05) before all comparatively treating, and treatment group therapeutic effect is significantly better than matched group.Clinical test results shows, and western medicine basis adds and uses medicine of the present invention, and that prevents and treats post-stroke depression has remarkable result, particularly in the time that post-stroke is longer, prevention effect of the present invention is more obvious, not easily produces drug resistance, safe without toxic side effect.
Model case
1, multitude X is strong, man, 59 years old, people from Liubei District, Liuzhou city, Guangxi province, because of " numb unable 4 months of left limb, dizziness 10 days " on March 10th, 2012 at encephalopathy section of Liuzhou City Chinese Medical Hospital hospitalization, be diagnosed as " 1, cerebral infarction; 2, poststroke depression ", through taking the embodiment of the present invention 6 capsule, each 3, every day 2 times, after taking 13 days continuously, on March 23rd, 2012, symptom improvement was left hospital.
2, yellow X group, female, 69 years old, people from mountain area was worn in Liujiang County, Liuzhou city, Guangxi province, because of " left limb unable January remaining " on March 13rd, 2012 at encephalopathy section of Liuzhou City Chinese Medical Hospital hospitalization, be diagnosed as " 1, cerebral infarction; 2, poststroke depression ", through taking the embodiment of the present invention 1 syrup, each 70ml, every day 2 times, take 19 days continuously, on April 2nd, 2012, symptom improvement was left hospital.
3, chapter X health, man, 75 years old, people from Chengzhong District, Liuzhou city, Guangxi province, because " left limb unable March more than, right side limb adynamia 1 month " gives December in 2011 15 days at encephalopathy section of Liuzhou City Chinese Medical Hospital hospitalization, be diagnosed as " 1, cerebral infarction; 2, poststroke depression ", through taking the embodiment of the present invention 2 tablet, each 3, every day 2 times, after taking 16 days continuously, taking a turn for the better in December in 2011 symptom on the 31st and leaving hospital.
Although above with general explanation, detailed description of the invention and test, the present invention is described in detail, and on basis of the present invention, can make some modifications or improvements it, this will be apparent to those skilled in the art.Therefore, these modifications or improvements without departing from theon the basis of the spirit of the present invention, all belong to the scope of protection of present invention.
Claims (8)
1. prevent and treat a strong medicine for post-stroke depression, it is characterized in that it is prepared from by the raw material of following weight portion: Herba Desmodii Triquetri (Herba Tadehagi Triquetri) 30-70 part, Caulis Polygoni Multiflori 20-50 part, dry root of Millettia pulchra(Dunn)Kurz var.laxior(Dunn)Z.Wei 20-50 part, bright red brill 30-80 part, Radix Paeoniae Alba 5-20 part.
2. the strong medicine of control post-stroke depression as claimed in claim 1, is characterized in that it is prepared from by the raw material of following weight portion: Herba Desmodii Triquetri (Herba Tadehagi Triquetri) 40-60 part, Caulis Polygoni Multiflori 35-45 part, dry root of Millettia pulchra(Dunn)Kurz var.laxior(Dunn)Z.Wei 30-40 part, bright red brill 35-45 part, Radix Paeoniae Alba 10-15 part.
3. the strong medicine of control post-stroke depression as claimed in claim 1, is characterized in that it is prepared from by the raw material of following weight portion: Herba Desmodii Triquetri (Herba Tadehagi Triquetri) 50 parts, Caulis Polygoni Multiflori 40 parts, dry root of Millettia pulchra(Dunn)Kurz var.laxior(Dunn)Z.Wei 35 parts, 40 parts, bright red brill, the Radix Paeoniae Alba 12 parts.
4. the strong medicine of the control post-stroke depression as described in claim 1-3 any one, is characterized in that its active component adopts the ethanol extraction of water extraction or 40-80% concentration expressed in percentage by volume to be prepared from.
5. the strong medicine of control post-stroke depression as claimed in claim 4, it is characterized in that its active component is prepared from by the following method: get whole 5 taste medical materials, extracting in water 2-3 time, each amount of water is equivalent to the 6-12 of medical material gross weight doubly, each extraction time is 1-3 hour, merge extractive liquid, filters, when filtrate is concentrated into 70-80 DEG C, relative density is the clear paste of 1.10-1.25, obtains described active component.
6. the strong medicine of control post-stroke depression as claimed in claim 4, it is characterized in that its active component is prepared from by the following method: get whole 5 taste medical materials, extracting in water 2-3 time, each amount of water is equivalent to the 6-12 of medical material gross weight doubly, each extraction time is 1-3 hour, merge extractive liquid, filter, when filtrate is concentrated into 70-80 DEG C, relative density is the clear paste of 1.05-1.20, add ethanol, alcohol content is made to be 40-70%, leave standstill 12-24 hour, filter, when filtrate is concentrated into 70-80 DEG C, relative density is the extractum of 1.10-1.25, obtain described active component.
7. the strong medicine of control post-stroke depression as claimed in claim 4, it is characterized in that its active component is prepared from by the following method: get whole 5 taste medical materials, with 40-80% alcohol reflux 2-3 time, each ethanol consumption is 4-10 times of medical material total amount, extraction time is 1-3 hour, merge extractive liquid, filters, when filtrate is concentrated into 60-80 DEG C, relative density is the extractum of 1.10-1.25, obtains described active component.
8. prevent and treat a strong medicine for post-stroke depression, in the strong medicine of the control post-stroke depression any one of claim 1-3 and pharmaceuticals industry, acceptable carrier prepares and forms.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310705502.XA CN103720791B (en) | 2013-12-19 | 2013-12-19 | A kind of strong medicine preventing and treating post-stroke depression and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310705502.XA CN103720791B (en) | 2013-12-19 | 2013-12-19 | A kind of strong medicine preventing and treating post-stroke depression and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103720791A CN103720791A (en) | 2014-04-16 |
| CN103720791B true CN103720791B (en) | 2015-11-18 |
Family
ID=50445253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310705502.XA Expired - Fee Related CN103720791B (en) | 2013-12-19 | 2013-12-19 | A kind of strong medicine preventing and treating post-stroke depression and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103720791B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104800640A (en) * | 2015-04-30 | 2015-07-29 | 李福军 | Medicine for treating dysthymia |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004352659A (en) * | 2003-05-29 | 2004-12-16 | Shiseido Co Ltd | External preparation for skin for bleaching |
| CN1994451A (en) * | 2006-12-27 | 2007-07-11 | 河南太龙药业股份有限公司 | Chinese medicinal composition for treating depression, its preparation method and application |
| CN101085246A (en) * | 2007-06-21 | 2007-12-12 | 张家港市晓阳食品有限公司 | Tea containing lotus heart and white peony root |
| WO2008119131A1 (en) * | 2007-04-02 | 2008-10-09 | Medcina Group Pty Ltd | Herbal compositions and methods for treating female infertility |
| CN102698053A (en) * | 2012-06-23 | 2012-10-03 | 陈慧婷 | Nacre Chinese herbal preparation for relieving depression and preparation method of same |
-
2013
- 2013-12-19 CN CN201310705502.XA patent/CN103720791B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004352659A (en) * | 2003-05-29 | 2004-12-16 | Shiseido Co Ltd | External preparation for skin for bleaching |
| CN1994451A (en) * | 2006-12-27 | 2007-07-11 | 河南太龙药业股份有限公司 | Chinese medicinal composition for treating depression, its preparation method and application |
| WO2008119131A1 (en) * | 2007-04-02 | 2008-10-09 | Medcina Group Pty Ltd | Herbal compositions and methods for treating female infertility |
| CN101085246A (en) * | 2007-06-21 | 2007-12-12 | 张家港市晓阳食品有限公司 | Tea containing lotus heart and white peony root |
| CN102698053A (en) * | 2012-06-23 | 2012-10-03 | 陈慧婷 | Nacre Chinese herbal preparation for relieving depression and preparation method of same |
Non-Patent Citations (1)
| Title |
|---|
| 鲍远程辨证治疗睡眠障碍临床经验;桂明进等;《中医药临床杂志》;20111231;第23卷(第12期);第1079-1080页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103720791A (en) | 2014-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102698097B (en) | Traditional Chinese medicinal composition for treating paradentitis, and formulation and preparation method thereof and toothpaste | |
| CN103099866A (en) | Traditional Chinese medicine composition for treating anxiety and insomnia and preparation method thereof | |
| CN102028375B (en) | Medicinal pillow for treating hypertension | |
| CN110123963A (en) | A kind of Chinese medicine sand table and its preparation method and application | |
| CN115837065B (en) | Traditional Chinese medicine composition and application thereof | |
| CN102526189B (en) | Chinese medicinal composition for treating angina pectoris | |
| CN103520504B (en) | Traditional Chinese medicine composition for treating cerebral apoplexy | |
| CN105687489A (en) | Drug for treating atopic dermatitis and preparation method and application thereof | |
| CN103720791B (en) | A kind of strong medicine preventing and treating post-stroke depression and preparation method thereof | |
| CN101816712A (en) | Chinese medicinal composition for treating trigeminal neuralgia | |
| CN102579804B (en) | Chinese medicine for treating stenocardia | |
| CN107184916B (en) | Traditional Chinese medicine composition with depression treatment effect, preparation method and application | |
| CN105213905A (en) | A kind of Chinese medicine composition and application thereof preventing and treating postmenopausal osteoporosis | |
| CN105168892A (en) | Chinese herbal preparation for treating hypoglycemia and preparing method of Chinese herbal preparation | |
| CN104906394A (en) | Traditional Chinese medicine for treating liver and kidney yin deficiency and qi and blood deficiency type hypertension | |
| CN106138637B (en) | Traditional Chinese medicine composition for promoting blood circulation, removing blood stasis, resisting rheumatism and relieving pain and preparation method thereof | |
| CN101249145B (en) | Nerves- soothing Chinese medicinal composition and its applications for preparing climacteric syndrome medicament | |
| CN104324134A (en) | Traditional Chinese medicine composition for improving microcirculation and preparation method of traditional Chinese medicine composition | |
| CN104740210B (en) | A kind of Chinese medicine and preparation method for the treatment of qi stagnation and blood stasis type craniocerebral trauma syndrome | |
| CN104740579B (en) | Premenstrual peace piece and its preparation technology | |
| CN102727773A (en) | Traditional Chinese medicinal capsule for treating blood mucoviscidosis | |
| CN102552423B (en) | Medicinal composition for treating migraine | |
| CN102872292A (en) | Traditional Chinese medicine for curing spleen and kidney deficiency type ischemic post-stroke depression | |
| CN103349709B (en) | Traditional Chinese medicine preparation capable of tonifying qi and yin and nourishing liver and kidney | |
| CN101862376B (en) | Medicament for treating oviduct obstructive infertility and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: WANG XIAOYUAN Free format text: FORMER OWNER: LIUZHOU CITY CHINESE MEDICAL HOSPITAL Effective date: 20150115 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Xiaoyuan Inventor before: Lu Changjun |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 545001 LIUZHOU, GUANGXI ZHUANG AUTONOMOUS REGION TO: 545000 LIUZHOU, GUANGXI ZHUANG AUTONOMOUS REGION Free format text: CORRECT: INVENTOR; FROM: LU CHANGJUN TO: WANG XIAOYUAN |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150115 Address after: 545000 No. 8, Plaza Road, the Guangxi Zhuang Autonomous Region, Liuzhou Applicant after: Wang Xiaoyuan Address before: 545001 Jiefang North Road, the Guangxi Zhuang Autonomous Region, Liuzhou, No. 32 Applicant before: Liuzhou Hospital of Traditional Chinese Medicine |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160520 Address after: 545001 Jiefang North Road, the Guangxi Zhuang Autonomous Region, Liuzhou, No. 32 Patentee after: Liuzhou Hospital of Traditional Chinese Medicine Address before: 545000 No. 8, Plaza Road, the Guangxi Zhuang Autonomous Region, Liuzhou Patentee before: Wang Xiaoyuan |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151118 Termination date: 20191219 |